Lantern Pharma (LTRN) announced on Monday the positive preliminary results from the Phase 2 HARMONIC study, which evaluated their drug candidate LP-300 in combination with chemotherapy agents pemetrexed and carboplatin in 'never smokers' with advanced non-small cell lung cancer (NSCLC).
The development of LP-300 was partially driven by Lantern's proprietary RADR, or Response Algorithm for Drug Positioning & Rescue. This platform integrates data analytics, experimental biology, biotechnology, and machine learning to enhance drug development and positioning.
In the Phase 2 lead-in cohort, comprising 7 patients, 6 patients showed clinical benefit from the LP-300 and chemotherapy combination, while 1 patient exhibited progressive disease. The clinical benefit rate and disease control rate for this group stand at 86%, with an objective response rate (ORR) of 43%.
Moreover, the preliminary data analysis indicated no additional safety concerns and no serious adverse events (SAEs) related to the treatment.
